Paul Winter

paul@handpen.com

Greetings,

I am the Webmaster for the Cancell Home page, a not-for-profit web site dedicated to uncovering the following false statement from the National Cancer Institute (NCI) regarding their testing of Cancell:

> "Preliminary tests were undertaken in 1990 and conducted twice for verification. The results of these tests indicated that Cancell did not demonstrate a biological effect considered worthy of further study."

The enclosed sheets are the actual test results obtained directly from NCI and show that the above NCI statement is a lie tantamount to mass murder.

Test Result Explanation

The following is the NCI initial in-vitro testing procedure for anti-tumor activity in an alleged cancer treatment compound:

1. Five different concentrations of the test compound are tested against 60 types of cancer tumors. This required 300 dishes containing cancer tumors and the compound under test.
2. Two days are allowed for the compound to work. This is actually too short for Cancell to have its full effect, but it is long enough for chemo to have its full effect.
3. Measure the change in weight of the tumors. Express this in percentage growth. A negative percentage growth is actually a shrinkage.
4. Record the percentage growth numbers in five columns and 60 rows. The five columns corresponds to the five different concentrations. Each of the 60 rows corresponds to a different type of tumor.

The Columns

To help understand the columns on pages 3, 4, and 5, number the columns from left to right.

Column 1 lists the tumor type tested.

Columns 4 to 8 define the five concentrations of the compound under test. This helps determine correct dosage for follow-on testing in animals.

Columns 9 to 13 contain the actual results expressed in percentage growth of the tumor. A reduction in mass is indicated by a negative number and indicates anti-cancer activity. There are five numbers for each tumor type corresponding to the five concentrations tested as defined in columns 4 to 8. Remember negative percentage growth is actually a shrinkage.

The following pages contain:

Page 2 - Fax cover sheet indicating the NSC number for Cancell

Page 3 - Cancell In-vitro Test Results from NCI

Page 4 - Test results for perilly alcohol - NSC 641066 containing no negative percentage growth numbers

Page 5 - Test results for taxol - NSC 125973 containing considerable negative percentage growth numbers

National Cancer Institute Developmental Therapeutics Program
In-Vitro Screening Data Review Checklist

NSC: 637907 -L / 1	Experiment ID: 9011NS78-9	Source:
Test Date: November 13, 1990	Review Date: January 10, 1991	

Pending Action by the NCI for this experiment

1. _____ None
2. ___X___ Repeat testing in the Primary Screen
3. _____ Refer to Biological Evaluation Committee
4. _____ Currently under Review by Biological Evaluation Committee

Comments

TO PAUL WINTER

IN VITRO ANTICANCER SCREENING DATA
FOR CANCELL (NSC 637907)
FOLLOWED BY INSTRUCTIONS FOR
INTERPRETATION.
NO IN VIVO DATA FOUND.

Anthony Manger, NCI

Figure 1. Fax Cover Sheet Indicating the NSC Number for Cancell Signed by Dr Manger, NIC

Figure 1 shows the NSC number for Cancell, 637907, and documents that the test results in Figure 2 are indeed the test results for Cancell.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC: 637907 -L / 1	**Experiment ID:** 9011NS78-9	**Test Type:** 08	**Units:** ug/ml
Report Date: October 27, 1997	**Test Date:** November 13, 1990	**QNS:**	**MC:**
COMI:	**Stain Reagent:** PROTEIN-51	**SSPL:**	

		Log10 Concentration										
	Time	Mean Optical Densities					Percent Growth					
Panel/Cell Line	Zero	Ctrl	0.9	1.9	2.9	3.9	0.9	1.9	2.9	3.9	GI50	TGI	LC50
Leukemia													
CCRF-CEM	0.189	0.780	0.268	0.186	0.188	0.184	13	-2	-1	-3	<8.00E+00	6.26E+01	>8.00E+03
HL-60(TB)	0.175	0.895	0.281	0.125	0.066	0.141	15	-28	-63	-19	<8.00E+00	1.76E+01	.
K-562	0.145	1.455	1.160	0.127	0.146	0.188	77	-12	.	3	1.62E+01	.	>8.00E+03
MOLT-4	0.315	1.700	0.748	0.276	0.323	0.315	31	-12	1	.	<8.00E+00	.	>8.00E+03
RPMI-8226	0.149	0.874	0.595	0.118	0.167	0.137	62	-21	2	-8	1.10E+01	.	>8.00E+03
SR	0.368	1.834	0.867	0.266	0.277	0.247	34	-28	-25	-33	<8.00E+00	2.85E+01	>8.00E+03
Non-Small Cell Lung Cancer													
A549/ATCC	0.292	1.757	1.104	0.149	0.214	0.236	55	-49	-27	-19	9.02E+00	2.71E+01	>8.00E+03
HOP-18	0.746	1.036	1.033	0.944	0.413	0.471	99	68	-45	-37	1.16E+02	3.22E+02	>8.00E+03
HOP-62	0.616	1.384	1.261	0.738	0.122	0.354	84	16	-80	-43	2.52E+01	1.17E+02	.
HOP-92	0.466	0.863	0.828	0.391	0.224	0.321	91	-16	-52	-31	1.93E+01	5.65E+01	.
NCI-H226	0.677	1.055	1.046	0.518	0.330	0.446	97	-24	-51	-34	1.97E+01	5.11E+01	.
NCI-H322M	0.436	1.418	1.158	-0.015	0.226	0.339	74	-100	-48	-22	1.09E+01	2.12E+01	.
NCI-H460	0.123	0.880	0.486	0.034	0.049	0.105	48	-72	-60	-15	<8.00E+00	2.00E+01	.
NCI-H522	0.446	1.408	0.739	0.062	0.274	0.367	31	-86	-39	-18	<8.00E+00	1.46E+01	.
LXFL 529	0.337	1.574	1.239	0.015	0.133	0.285	73	-96	-61	-15	1.09E+01	2.17E+01	.
Small Cell Lung Cancer													
DMS 114	0.484	1.334	0.668	0.067	0.125	0.327	22	-86	-74	-32	<8.00E+00	1.27E+01	.
DMS 273	0.198	1.649	1.067	0.064	0.113	0.169	60	-68	-43	-15	9.55E+00	2.35E+01	.
Colon Cancer													
COLO 205	0.211	0.854	0.775	0.005	0.014	0.103	88	-98	-93	-51	1.28E+01	2.38E+01	4.43E+01
DLD-1	0.197	1.099	0.891	0.122	0.153	0.178	77	-38	-23	-10	1.37E+01	3.73E+01	>8.00E+03
HCC-2998	0.610	1.775	1.567	0.711	0.193	0.376	82	9	-68	-38	2.19E+01	1.04E+02	.
HCT-116	0.130	1.172	0.869	0.001	0.006	0.047	71	-99	-96	-64	1.06E+01	2.09E+01	4.11E+01
HCT-15	0.332	1.713	1.230	0.037	0.111	0.208	65	-89	-67	-37	1.00E+01	2.11E+01	.
HT29	0.280	1.487	1.301	0.155	0.116	0.199	85	-45	-59	-29	1.48E+01	3.62E+01	.
KM12	0.465	2.194	1.626	0.259	0.052	0.433	67	-44	-89	-7	1.14E+01	3.20E+01	.
KM20L2	0.351	1.640	1.464	0.127	0.105	0.223	86	-64	-70	-36	1.40E+01	3.00E+01	.
SW-620	0.120	1.010	0.802	0.025	0.091	0.076	77	-80	-24	-37	1.18E+01	2.48E+01	.
CNS Cancer													
SF-268	0.404	1.629	1.147	0.067	0.250	0.345	61	-84	-38	-15	9.48E+00	2.11E+01	.
SF-295	0.325	1.542	1.479	0.018	0.147	0.265	95	-95	-55	-19	1.38E+01	2.53E+01	.
SF-539	0.504	1.601	1.351	0.516	0.221	0.464	77	1	-56	-8	1.82E+01	8.36E+01	.
SNB-19	0.492	1.361	1.240	0.961	0.048	0.304	86	54	-90	-38	8.51E+01	1.89E+02	.
SNB-75	0.571	0.841	0.829	0.385	0.112	0.382	95	-33	-80	-33	1.81E+01	4.45E+01	.
SNB-78	0.442	1.111	0.978	0.298	0.296	0.280	80	-33	-33	-37	1.48E+01	4.11E+01	>8.00E+03
U251	0.289	1.354	1.052	0.004	0.066	0.248	72	-99	-77	-14	1.07E+01	2.11E+01	.
Melanoma													
LOX IMVI	0.223	1.280	0.853	0.004	0.007	0.067	60	-98	-97	-70	9.20E+00	1.91E+01	3.97E+01
MALME-3M	0.559	1.230	1.062	0.779	0.235	0.381	75	33	-58	-32	3.12E+01	1.84E+02	.
M14	0.251	1.127	0.940	0.005	0.059	0.224	79	-98	-76	-11	1.16E+01	2.23E+01	.
M19-MEL	0.319	1.130	0.824	0.046	0.091	0.227	62	-86	-72	-29	9.67E+00	2.11E+01	.
SK-MEL-2	0.514	1.322	1.265	0.684	0.344	0.461	93	21	-33	-10	3.16E+01	1.95E+02	>8.00E+03
SK-MEL-28	0.301	0.998	0.928	0.174	0.149	0.267	90	-42	-50	-12	1.60E+01	3.83E+01	.
SK-MEL-5	0.335	1.747	1.285	0.014	0.039	0.205	67	-96	-88	-39	1.02E+01	2.07E+01	.
UACC-257	0.532	1.339	1.204	0.046	0.118	0.278	83	-91	-78	-48	1.24E+01	2.40E+01	.
UACC-62	0.488	1.587	1.364	0.005	0.058	0.350	80	-99	-88	-28	1.17E+01	2.24E+01	.
Ovarian Cancer													
IGROV1	0.523	1.673	1.487	0.945	0.310	0.395	84	37	-41	-25	4.18E+01	2.38E+02	>8.00E+03
OVCAR-3	0.441	1.357	1.061	0.001	0.168	0.341	68	-100	-62	-23	1.02E+01	2.03E+01	.
OVCAR-4	0.387	0.910	0.792	0.021	0.248	0.342	78	-95	-36	-12	1.16E+01	2.25E+01	.
OVCAR-5	0.556	1.063	1.024	0.002	0.004	0.197	92	-100	-99	-65	1.33E+01	2.42E+01	4.41E+01
OVCAR-8	0.239	1.413	1.085	0.043	0.096	0.243	72	-82	-60	0	1.11E+01	.	.
SK-OV-3	0.316	0.896	0.870	0.303	0.169	0.221	96	-4	-46	-30	2.29E+01	7.30E+01	>8.00E+03
Renal Cancer													
786-0	0.158	1.106	0.787	-0.001	0.029	0.146	66	-100	-81	-7	1.00E+01	2.00E+01	.
A498	0.658	1.314	1.270	1.014	0.094	0.229	93	54	-86	-65	8.58E+01	1.95E+02	4.45E+02
ACHN	0.529	1.652	1.260	0.437	0.098	0.469	65	-17	-82	-11	1.22E+01	4.92E+01	.
CAKI-1	0.540	1.336	1.273	0.932	0.420	0.445	92	49	-22	-18	7.68E+01	3.91E+02	>8.00E+03
RXF 393	0.633	0.898	0.846	0.022	0.016	0.278	81	-97	-98	-56	1.19E+01	2.28E+01	4.37E+01
RXF-631	0.440	1.833	0.914	0.345	0.329	0.311	34	-22	-25	-29	<8.00E+00	3.27E+01	>8.00E+03
SN12C	0.396	1.489	1.208	0.008	0.151	0.355	74	-98	-62	-11	1.11E+01	2.16E+01	.
TK-10	1.358	1.921	1.938	1.589	0.653	-0.036	103	41	-52	-100	5.73E+01	2.21E+02	7.63E+02
UO-31	0.618	1.186	1.128	0.928	0.065	0.438	90	55	-90	-29	8.61E+01	1.91E+02	.

Figure 2. Cancell In-vitro Test Results from NCI

Note that the Percentage Growth column contains many negative growth numbers indicating that tumors shrank during the test period.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC: 641066 -T / 2	**Experiment ID:** 9307NS90-39	**Test Type:** 08	**Units:** Molar
Report Date: October 27, 1997	**Test Date:** July 19, 1993	**QNS:**	**MC:**
COMI:	**Stain Reagent:** SRB Dual-P	**SSPL:**	

			Log10 Concentration											
	Time		Mean Optical Densities					Percent Growth						
Panel/Cell Line	Zero	Ctrl	-9.0	-8.0	-7.0	-6.0	-5.0	-9.0	-8.0	-7.0	-6.0	-5.0	GI50	TGI	LC50
Leukemia															
CCRF-CEM	0.266	0.991	0.960	1.028	0.905	1.047	0.950	96	105	88	108	94	>1.00E-05	>1.00E-05	>1.00E-05
HL-60(TB)	0.232	1.039	1.000	1.016	1.112	0.998	0.915	95	97	109	95	85	>1.00E-05	>1.00E-05	>1.00E-05
K-562	0.140	1.143	1.041	1.123	0.856	1.151	1.020	90	98	71	101	88	>1.00E-05	>1.00E-05	>1.00E-05
MOLT-4	0.354	2.126	2.011	2.011	1.921	1.707	1.395	93	93	88	76	59	>1.00E-05	>1.00E-05	>1.00E-05
RPMI-8226	0.401	2.147	1.942	1.901	1.861	1.920	1.493	88	86	84	87	63	>1.00E-05	>1.00E-05	>1.00E-05
SR	0.227	1.326	1.344	1.387	1.064	1.169	0.796	102	106	76	86	52	>1.00E-05	>1.00E-05	>1.00E-05
Non-Small Cell Lung Cancer															
A549/ATCC	0.370	1.479	1.446	1.396	1.472	1.461	1.333	97	93	99	98	87	>1.00E-05	>1.00E-05	>1.00E-05
EKVX	0.635	1.101	1.081	1.053	1.053	1.003	0.870	96	90	90	79	51	>1.00E-05	>1.00E-05	>1.00E-05
HOP-62	0.671	1.465	1.375	1.448	1.454	1.400	1.227	89	98	99	92	70	>1.00E-05	>1.00E-05	>1.00E-05
HOP-92	0.673	1.012	0.934	0.970	0.976	0.956	0.867	77	88	89	83	57	>1.00E-05	>1.00E-05	>1.00E-05
NCI-H226	0.853	1.350	1.358	1.293	1.372	1.266	1.264	102	88	105	83	83	>1.00E-05	>1.00E-05	>1.00E-05
NCI-H23	0.531	1.334	1.419	1.335	1.346	1.366	1.281	111	100	101	104	93	>1.00E-05	>1.00E-05	>1.00E-05
NCI-H322M	0.806	1.699	1.695	1.666	1.678	1.678	1.487	100	96	98	98	76	>1.00E-05	>1.00E-05	>1.00E-05
NCI-H460	0.259	1.568	1.554	1.529	1.558	1.525	1.470	99	97	99	97	92	>1.00E-05	>1.00E-05	>1.00E-05
NCI-H522	0.523	1.366	1.507	1.461	1.400	1.291	1.272	117	111	104	91	89	>1.00E-05	>1.00E-05	>1.00E-05
Colon Cancer															
COLO 205	0.373	1.409	1.369	1.400	1.379	1.365	1.445	96	99	97	96	103	>1.00E-05	>1.00E-05	>1.00E-05
HCC-2998	0.556	1.514	1.501	1.492	1.494	1.438	1.271	99	98	98	92	75	>1.00E-05	>1.00E-05	>1.00E-05
HCT-116	0.205	0.995	0.959	0.997	0.899	1.004	0.814	96	100	88	101	77	>1.00E-05	>1.00E-05	>1.00E-05
HCT-15	0.392	1.926	1.791	1.625	1.831	1.615	1.538	91	80	94	80	75	>1.00E-05	>1.00E-05	>1.00E-05
HT29	0.325	1.654	1.738	1.674	1.728	1.615	1.587	106	101	106	97	95	>1.00E-05	>1.00E-05	>1.00E-05
KM12	0.465	1.667	1.693	1.707	1.749	1.783	1.807	102	103	107	110	112	>1.00E-05	>1.00E-05	>1.00E-05
CNS Cancer															
SF-268	0.668	1.506	1.508	1.452	1.408	1.380	1.400	100	93	88	85	87	>1.00E-05	>1.00E-05	>1.00E-05
SF-295	0.359	0.946	0.946	0.964	0.922	0.913	0.831	100	103	96	94	80	>1.00E-05	>1.00E-05	>1.00E-05
SF-539	0.581	1.467	1.377	1.302	1.319	1.236	1.128	90	81	83	74	62	>1.00E-05	>1.00E-05	>1.00E-05
SNB-19	0.858	1.416	1.401	1.393	1.400	1.349	1.196	97	96	97	88	61	>1.00E-05	>1.00E-05	>1.00E-05
SNB-75	0.595	1.047	1.062	1.083	1.044	1.004	0.859	103	108	99	90	58	>1.00E-05	>1.00E-05	>1.00E-05
U251	0.308	1.242	1.240	1.168	1.206	1.153	0.960	100	92	96	90	70	>1.00E-05	>1.00E-05	>1.00E-05
Melanoma															
LOX IMVI	0.319	1.063	1.077	1.049	1.045	1.066	1.040	102	98	98	100	97	>1.00E-05	>1.00E-05	>1.00E-05
MALME-3M	0.702	1.319	1.293	1.328	1.286	1.288	1.200	96	101	95	95	81	>1.00E-05	>1.00E-05	>1.00E-05
M14	0.284	1.209	1.179	1.164	1.185	1.090	1.179	97	95	97	87	97	>1.00E-05	>1.00E-05	>1.00E-05
SK-MEL-2	0.780	1.284	1.251	1.275	1.313	1.238	1.299	93	98	106	91	103	>1.00E-05	>1.00E-05	>1.00E-05
SK-MEL-28	0.492	1.087	1.153	1.089	1.102	1.115	1.092	111	100	103	105	101	>1.00E-05	>1.00E-05	>1.00E-05
SK-MEL-5	0.374	1.459	1.574	1.391	1.503	1.330	1.176	111	94	104	88	74	>1.00E-05	>1.00E-05	>1.00E-05
UACC-257	0.655	1.525	1.552	1.528	1.537	1.520	1.455	103	100	101	99	92	>1.00E-05	>1.00E-05	>1.00E-05
UACC-62	0.531	1.332	1.347	1.313	1.297	1.256	1.049	102	98	96	91	65	>1.00E-05	>1.00E-05	>1.00E-05
Ovarian Cancer															
IGROV1	0.572	1.393	1.362	1.401	1.360	1.408	1.490	96	101	96	102	112	>1.00E-05	>1.00E-05	>1.00E-05
OVCAR-3	0.510	1.391	1.373	1.370	1.385	1.344	1.226	98	98	99	95	81	>1.00E-05	>1.00E-05	>1.00E-05
OVCAR-4	0.543	1.139	1.164	1.122	1.228	1.197	1.145	104	97	115	110	101	>1.00E-05	>1.00E-05	>1.00E-05
OVCAR-5	0.737	1.416	1.391	1.444	1.466	1.411	1.351	96	104	107	99	90	>1.00E-05	>1.00E-05	>1.00E-05
OVCAR-8	0.384	1.413	1.453	1.444	1.421	1.375	1.190	104	103	101	96	78	>1.00E-05	>1.00E-05	>1.00E-05
SK-OV-3	0.545	1.080	1.122	1.080	1.125	1.112	1.057	108	100	109	106	96	>1.00E-05	>1.00E-05	>1.00E-05
Renal Cancer															
786-0	0.233	1.101	1.120	1.080	1.003	0.975	0.887	102	98	89	85	75	>1.00E-05	>1.00E-05	>1.00E-05
A498	0.900	1.595	1.459	1.521	1.524	1.414	1.278	80	89	90	74	54	>1.00E-05	>1.00E-05	>1.00E-05
ACHN	0.701	1.894	1.879	1.857	1.871	1.929	1.862	99	97	98	103	97	>1.00E-05	>1.00E-05	>1.00E-05
CAKI-1	0.465	1.405	1.489	1.446	1.519	1.489	1.377	109	104	112	109	97	>1.00E-05	>1.00E-05	>1.00E-05
RXF 393	0.689	1.345	1.315	1.326	1.352	1.253	1.186	95	97	101	86	76	>1.00E-05	>1.00E-05	>1.00E-05
SN12C	0.475	1.362	1.344	1.268	1.336	1.275	1.130	98	89	97	90	74	>1.00E-05	>1.00E-05	>1.00E-05
TK-10	1.395	1.838	1.897	1.954	1.935	1.957	1.941	113	126	122	127	123	>1.00E-05	>1.00E-05	>1.00E-05
UO-31	0.662	1.871	1.902	1.855	1.885	1.724	1.558	103	99	101	88	74	>1.00E-05	>1.00E-05	>1.00E-05
Prostate Cancer															
PC-3	0.586	1.881	1.823	1.852	1.784	1.714	1.530	96	98	93	87	73	>1.00E-05	>1.00E-05	>1.00E-05
DU-145	1.594	2.648	2.809	2.811	2.778	2.697	2.668	115	116	112	105	102	>1.00E-05	>1.00E-05	>1.00E-05
Breast Cancer															
MCF7	0.373	1.500	1.485	1.482	1.472	1.446	1.290	99	98	98	95	81	>1.00E-05	>1.00E-05	>1.00E-05
NCI/ADR-RES	0.442	1.249	1.201	1.265	1.297	1.229	1.100	94	102	106	98	81	>1.00E-05	>1.00E-05	>1.00E-05
MDA-MB-231/ATCC	0.382	0.891	0.813	0.820	0.939	0.901	0.931	85	86	110	102	108	>1.00E-05	>1.00E-05	>1.00E-05
HS 578T	0.596	1.219	1.209	1.195	1.192	1.105	1.044	99	96	96	82	72	>1.00E-05	>1.00E-05	>1.00E-05
MDA-MB-435	0.339	1.172	1.177	1.148	1.148	1.062	1.053	101	97	97	87	86	>1.00E-05	>1.00E-05	>1.00E-05
MDA-N	0.259	1.438	1.362	1.427	1.414	1.468	1.195	94	99	98	103	79	>1.00E-05	>1.00E-05	>1.00E-05
BT-549	0.477	0.804	0.806	0.784	0.792	0.774	0.729	101	94	96	91	77	>1.00E-05	>1.00E-05	>1.00E-05
T-47D	0.607	1.064	1.095	1.081	1.086	1.010	0.949	107	104	105	88	75	>1.00E-05	>1.00E-05	>1.00E-05

Figure 3. Perilly Alcohol In-vitro Test Results from NCI

Figure 3 shows the test results for a truly inactive compound that did not reduce the growth of tumors. Use this data as a base line; any percentage growth that is less than these numbers indicated that tumor growth was retarded. Negative percentage growth numbers indicate that the tumor mass was reduced.

National Cancer Institute Developmental Therapeutics Program
In-Vitro Testing Results

NSC: 125973 -L / 19	**Experiment ID:** 9706LM48-11	**Test Type:** 09	**Units:** Molar
Report Date: November 3, 1997	**Test Date:** June 30, 1997	**QNS:**	**MC:**
COMI:	**Stain Reagent:** SRB Dual-P	**SSPL:**	

		Log10 Concentration												
	Time	Mean Optical Densities					Percent Growth							
Panel/Cell Line	Zero	Ctrl	-10.0	-9.0	-8.0	-7.0	-6.0	-10.0	-9.0	-8.0	-7.0	-6.0	GI50	TGI	LC50
Leukemia															
HL-60(TB)	0.008	1.924	1.286	1.173	0.411	0.032	0.006	67	61	21	1	-25	1.87E-09	1.12E-07	>1.00E-06
K-562	0.006	2.790	2.898	2.702	2.970	0.340	-0.005	104	97	106	12	-100	3.96E-08	1.28E-07	3.58E-07
MOLT-4	0.015	1.560	1.146	1.237	0.157	0.024	0.021	73	79	9	1	0	2.61E-09	>1.00E-06	>1.00E-06
RPMI-8226	0.104	2.300	2.207	2.281	0.226	0.080	0.063	96	99	6	-23	-39	3.35E-09	1.56E-08	>1.00E-06
SR	-0.002	0.405	0.245	0.311	0.257	-0.006	0.001	61	77	64	200	1	5.65E-07	>1.00E-06	>1.00E-06
Non-Small Cell Lung Cancer															
A549/ATCC	0.034	3.024	2.963	2.944	1.865	0.133	0.077	98	97	61	3	1	1.56E-08	>1.00E-06	>1.00E-06
EKVX	0.038	0.880	0.827	0.822	0.641	0.266	0.085	94	93	72	27	6	3.06E-08	>1.00E-06	>1.00E-06
HOP-62	0.050	1.018	1.046	1.087	0.599	0.104	0.042	103	107	57	6	-17	1.35E-08	1.76E-07	>1.00E-06
HOP-92	0.151	0.808	0.769	0.761	0.654	0.324	0.281	94	93	76	26	20	3.37E-08	>1.00E-06	>1.00E-06
NCI-H226	0.081	0.531	0.492	0.538	0.229	0.035	0.024	91	101	33	-57	-70	5.61E-09	2.32E-08	8.40E-08
NCI-H23	0.069	0.989	1.034	0.946	0.644	0.043	0.046	105	95	63	-38	-33	1.33E-08	4.16E-08	>1.00E-06
NCI-H322M	0.040	0.905	0.759	0.785	0.614	0.083	0.037	83	86	66	5	-9	1.85E-08	2.30E-07	>1.00E-06
NCI-H460	0.032	1.989	1.977	1.940	2.059	0.082	0.001	99	97	104	3	-98	3.39E-08	1.06E-07	3.31E-07
NCI-H522	0.072	0.727	0.756	0.708	0.168	-0.002	0.003	104	97	15	-100	-97	3.73E-09	1.34E-08	3.66E-08
Colon Cancer															
COLO 205	0.011	0.822	0.798	0.765	0.323	-0.020	-0.019	97	93	38	-100	-100	6.14E-09	1.90E-08	4.35E-08
HCT-116	0.002	1.118	1.238	0.674	0.335	-0.009	-0.018	111	60	30	-100	-100	2.17E-09	1.70E-08	4.12E-08
HCT-15	0.038	2.783	2.696	2.636	2.853	2.543	0.693	97	95	103	91	24	4.10E-07	>1.00E-06	>1.00E-06
HT29	0.028	3.052	2.964	3.027	0.331	0.008	-0.001	97	99	10	-71	-100	3.56E-09	1.33E-08	5.46E-08
KM12	0.013	1.482	1.331	1.380	0.848	0.070	0.044	90	93	57	4	2	1.34E-08	>1.00E-06	>1.00E-06
SW-620	0.012	2.837	2.791	2.811	1.941	0.042	0.021	98	99	68	1	0	1.87E-08	>1.00E-06	>1.00E-06
RKOp53RE1	0.003	1.638	1.651	1.294	0.054	-0.006	-0.008	101	79	3	-100	-100	2.41E-09	1.07E-08	3.27E-08
HT29p53RE22	0.086	3.683	3.385	3.192	2.438	0.417	0.059	92	86	65	9	-31	1.88E-08	1.68E-07	>1.00E-06
H1299p53RE29	0.044	2.838	2.359	2.354	2.010	0.515	0.071	83	83	70	17	1	2.40E-08	>1.00E-06	>1.00E-06
RKO Waf1	0.007	3.178	3.001	2.815	0.410	0.100	0.036	94	89	13	3	1	3.22E-09	>1.00E-06	>1.00E-06
CNS Cancer															
SF-268	0.091	1.716	1.537	1.526	0.841	0.094	0.051	89	88	46	0	-44	8.12E-09	1.01E-07	>1.00E-06
SF-539	0.020	1.363	1.314	1.178	0.117	0.059	0.038	96	86	7	3	1	2.87E-09	>1.00E-06	>1.00E-06
SNB-19	0.028	1.640	1.581	1.542	1.021	0.047	0.005	96	94	62	1	-82	1.56E-08	1.03E-07	4.11E-07
SNB-75	0.227	1.484	1.424	1.428	1.162	0.340	0.217	95	96	74	9	-4	2.36E-08	4.68E-07	>1.00E-06
U251	0.040	2.456	2.394	2.384	1.761	0.039	0.006	97	97	71	-4	-85	1.92E-08	8.91E-08	3.71E-07
Melanoma															
LOX IMVI	0.026	1.766	1.367	1.386	0.180	0.029	0.016	77	78	9	0	-40	2.55E-09	1.01E-07	>1.00E-06
MALME-3M	0.068	1.103	0.987	0.961	0.209	0.083	0.094	89	86	14	1	3	3.16E-09	>1.00E-06	>1.00E-06
M14	0.028	1.707	1.547	1.504	1.180	0.052	-0.010	90	88	69	1	-100	1.89E-08	1.03E-07	3.21E-07
SK-MEL-2	0.201	1.839	1.663	1.703	1.246	0.148	0.097	89	92	64	-26	-52	1.42E-08	5.10E-08	8.54E-07
SK-MEL-28	0.059	1.773	1.593	1.535	0.616	0.132	0.062	89	86	32	4	0	4.72E-09	>1.00E-06	>1.00E-06
UACC-257	0.062	1.495	1.371	1.365	0.232	0.125	0.070	91	91	12	4	1	3.29E-09	>1.00E-06	>1.00E-06
UACC-62	0.098	1.549	1.661	1.505	1.404	0.034	0.032	108	97	90	-66	-68	1.81E-08	3.78E-08	7.92E-08
Ovarian Cancer															
IGROV1	0.044	1.893	1.821	1.867	0.327	0.128	0.087	96	99	15	5	2	3.83E-09	>1.00E-06	>1.00E-06
OVCAR-3	0.071	1.231	1.228	1.141	0.545	0.015	.	100	92	41	-79	-100	6.64E-09	2.19E-08	5.74E-08
OVCAR-4	0.135	1.839	1.851	1.691	1.122	0.154	0.147	101	91	58	1	1	1.38E-08	>1.00E-06	>1.00E-06
OVCAR-5	0.043	1.347	1.257	1.262	0.747	0.131	0.073	93	93	54	7	2	1.21E-08	>1.00E-06	>1.00E-06
OVCAR-8	0.032	1.617	1.640	1.646	1.422	0.007	0.001	101	102	88	-78	-97	1.69E-08	3.38E-08	6.77E-08
SK-OV-3	0.044	0.776	0.721	0.730	0.521	0.142	0.086	92	94	65	13	6	1.96E-08	>1.00E-06	>1.00E-06
Renal Cancer															
A498	0.084	1.125	0.929	1.058	1.095	0.760	0.108	81	94	97	65	2	1.73E-07	>1.00E-06	>1.00E-06
ACHN	0.022	1.771	1.760	1.645	1.233	0.257	0.019	99	93	69	13	-14	2.21E-08	3.13E-07	>1.00E-06
CAKI-1	0.056	0.762	0.711	0.735	0.580	0.186	0.102	93	96	74	18	7	2.71E-08	>1.00E-06	>1.00E-06
RXF 393	0.152	1.089	1.030	1.029	0.714	0.165	0.068	94	94	60	1	-55	1.48E-08	1.06E-07	8.07E-07
SN12C	0.042	1.257	1.230	1.248	0.747	0.023	0.006	98	99	58	-45	-86	1.20E-08	3.65E-08	1.31E-07
TK-10	0.066	1.164	0.997	1.056	0.968	0.568	0.130	85	90	82	46	6	7.60E-08	>1.00E-06	>1.00E-06
UO-31	0.181	2.081	2.192	2.127	2.170	2.091	1.273	106	102	105	101	57	>1.00E-06	>1.00E-06	>1.00E-06
Prostate Cancer															
PC-3	0.051	3.276	2.888	2.937	1.902	0.102	0.088	88	89	57	2	1	1.36E-08	>1.00E-06	>1.00E-06
DU-145	0.135	1.817	1.709	1.722	1.505	0.018	-0.011	94	94	81	-87	-100	1.54E-08	3.05E-08	6.05E-08
Breast Cancer															
MCF7	0.035	2.605	2.569	2.368	1.068	0.156	0.138	99	91	40	5	4	6.40E-09	>1.00E-06	>1.00E-06
NCI/ADR-RES	0.062	1.708	1.683	1.692	1.663	1.518	1.181	98	99	97	88	68	>1.00E-06	>1.00E-06	>1.00E-06
MDA-MB-231/ATCC	0.042	0.884	0.709	0.679	0.494	0.036	0.021	79	76	54	-14	-50	1.13E-08	6.16E-08	>1.00E-06
HS 578T	0.106	1.110	0.995	0.968	0.333	0.058	0.033	89	86	23	-45	-69	3.69E-09	2.17E-08	1.63E-07
MDA-MB-435	0.019	1.070	0.881	0.815	0.034	0.004	-0.006	82	76	1	-79	-100	2.22E-09	1.04E-08	4.36E-08
MDA-N	0.031	1.629	1.536	1.664	0.078	-0.015	-0.017	94	102	3	-100	-100	3.36E-09	1.07E-08	3.27E-08
BT-549	0.133	0.909	0.901	0.725	0.414	0.008	0.001	99	76	36	-94	-100	4.54E-09	1.89E-08	4.57E-08
T-47D	0.060	0.532	0.496	0.507	0.340	0.118	0.088	92	95	59	12	6	1.58E-08	>1.00E-06	>1.00E-06
MCF7-E6	0.044	1.363	1.360	1.363	0.341	0.124	0.179	100	100	23	6	10	4.42E-09	>1.00E-06	>1.00E-06

Figure 4. Taxol In-vitro Test Results from NCI